Bajaj Healthcare Ltd
Established in the year 1993, Bajaj Healthcare Ltd is an estalished player in the Indian Pharmacuetical Industry and fastest growing mid-cap pharmaceutical companies in India.[1]
It is a bulk drug manufacturer manufacturing and supply of various Active Pharmaceutical Ingredients (API's), Amino acids and Nutritional supplements for Pharmaceuticals, Neutraceuticals, Food industries. [2]
- Market Cap ₹ 807 Cr.
- Current Price ₹ 292
- High / Low ₹ 513 / 245
- Stock P/E 28.0
- Book Value ₹ 115
- Dividend Yield 0.34 %
- ROCE 11.9 %
- ROE 12.4 %
- Face Value ₹ 5.00
Pros
Cons
- Company might be capitalizing the interest cost
- Debtor days have increased from 92.4 to 123 days.
- Working capital days have increased from 146 days to 204 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
142 | 171 | 205 | 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 673 | 494 | |
130 | 158 | 186 | 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 566 | 411 | |
Operating Profit | 11 | 13 | 19 | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 107 | 82 |
OPM % | 8% | 7% | 9% | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 16% | 17% |
0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | 2 | -76 | |
Interest | 5 | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 23 | 30 |
Depreciation | 6 | 8 | 9 | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 27 | 25 |
Profit before tax | 1 | -2 | 3 | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -49 |
Tax % | 38% | 31% | 40% | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 26% | |
1 | -1 | 2 | 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -50 | |
EPS in Rs | 0.72 | -1.18 | 2.19 | 8.34 | 3.04 | 2.83 | 5.50 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -18.22 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 16% |
3 Years: | 18% |
TTM: | -26% |
Compounded Profit Growth | |
---|---|
10 Years: | 46% |
5 Years: | 23% |
3 Years: | 19% |
TTM: | -59% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 7% |
1 Year: | 1% |
Return on Equity | |
---|---|
10 Years: | 19% |
5 Years: | 21% |
3 Years: | 23% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 |
Reserves | 27 | 26 | 28 | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 302 |
Preference Capital | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
61 | 70 | 70 | 69 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 357 | |
32 | 33 | 45 | 40 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 119 | 165 | |
Total Liabilities | 121 | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 901 | 838 |
46 | 54 | 56 | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 245 | |
CWIP | 13 | 5 | 3 | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 14 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
63 | 72 | 87 | 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 514 | 579 | |
Total Assets | 121 | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 901 | 838 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 14 | 17 | 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | |
-15 | -8 | -9 | -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | |
6 | -7 | -8 | -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 132 | |
Net Cash Flow | 0 | -0 | 1 | -0 | -0 | 0 | 7 | -0 | -4 | 10 | -12 | 16 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 90 | 95 | 98 | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 123 |
Inventory Days | 58 | 43 | 51 | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 191 |
Days Payable | 60 | 51 | 68 | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 78 |
Cash Conversion Cycle | 87 | 87 | 81 | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 237 |
Working Capital Days | 62 | 71 | 62 | 52 | 52 | 58 | 61 | 66 | 76 | 90 | 142 | 204 |
ROCE % | 7% | 5% | 10% | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 12% |
Documents
Announcements
- Closure of Trading Window 14h
- Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) 1d
-
Announcement under Regulation 30 (LODR)-Credit Rating
7 Mar - Under Reg. 30 of SEBI LODR Regulations, 2015 for withdrawal of credit rating
- Announcement under Regulation 30 (LODR)-Credit Rating 2 Mar
- Intimation Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015 28 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Product Portfolio
The Co. is into manufacturing and supply of API's, Intermediates, Formulations and Impurities. [1]
With 6 API manufacturing facilities spread across different states, API contributes around 90% to the overall revenue mix. It has a strong presence in more than 50 countries through exports of API's with an aggregate manufacturing capacity of 730 MT per month. [2]